We are proud to announce our latest milestone at Enveda: FDA IND clearance and first patient dosed for ENV-308, our first-in-class oral therapy for obesity. GLP-1s changed expectations for weight loss. But they also raised challenging questions: Can patients stay on them long term? What happens after weight loss? Who can realistically access injectable medicines on a global scale? ENV-308 is a once-daily oral small molecule designed with exciting potential for durability, tolerability, and real-world use. It’s built for long-term metabolic health, not just short-term weight loss. And it’s designed to fit into everyday life, earlier in care and over years, not months. Obesity is a chronic disease. Solving it at the population scale will require new tools, new thinking, and medicines designed to last. This milestone is a first step. And yes, we are now a multi-asset clinical-stage company! Read more: tinyurl.com/835rd7jc

Raising $150M wasn’t the only headline. Discovery is nothing without delivery ENV-294, our lead drug for #atopicdermatitis, has entered Phase 1b. A completely new way of tackling this disease, and potentially others across #inflammation, is playing out in patients. Experience that shapes the industry Mikael Dolsten joins Enveda. Former CSO of Pfizer, with 36 approvals and 150 candidates. He knows what it takes to turn science into #medicines that matter. This is just the beginning. Read more in our announcement: businesswire.com/news/home/2…

Celebrating another incredible milestone for @wireframe family co @lifeschemistry. Using AI to find new cures from nature & power a diverse pipeline of high value assets entering the clinic.

Exciting milestone for Argon AI—we’ve raised a $5.5 million seed round led by @CrosslinkCap and @WireframeVC , with support from @ycombinator , @pioneer_fund , and industry operators. Grateful to our customers for their trust and our investors @ThePhilBoyer, @harsh1, @DaveMessina, @SurbhiSarnaSF and countless others for believing in Argon's vision. We believe AI will fundamentally reshape how biopharma companies and life science consultancies operate. Argon's mission is to give biopharma & life science consulting teams an AI-native workspace that turns scattered data into decision-ready insights in minutes—not weeks. Early partners are already elevating their teams away from the data-drudgery that plagues the industry towards higher-order tasks — science, strategy, and domain specific taste and intent. This capital lets us accelerate building new products and features to delight our partners. And huge kudos to the Argon team—your speed and grit make the impossible routine! Onward!

Proud to see portco @PhytoformLabs team up with @corteva to deploy AI‑driven gene editing on corn—fine‑tuning two native genes for disease resilience without GMOs. Another milestone pushing biotech from lab to field 🌍🌽 agfundernews.com/phytoform-a…

“Our mission isn't just to uncover nature's chemistry, it's to translate these discoveries into treatments that could change lives today.” Enveda’s founder @viswacolluru spoke with @bbc about how life’s chemistry is a critical source of new medicines in #TheNextFrontier series.

On the cover… The Great Unknown: Chemistry’s Untapped Frontier in Understanding Life Behind every groundbreaking biological discovery lies a hidden chemical dance—millions of unseen reactions occurring every second. Our research published in @GENBiotechJrnl spotlights #chemistry as biology’s final frontier and how AI is elucidating these invisible reactions. This insight will revolutionize and redefine our understanding of not just life, but what it means to be alive. Honored and excited to see our work featured on the cover of GEN Biotechnology Journal! It’s time for chemistry to take center stage. Read the full article written by our very own Dan Wee, PhD and Tendai Chisowa, PhD: doi.org/10.1089/genbio.2025.… Thank you to @xiaofei_lin and @KevinADavies from @GENbio

Looking for cracked entrepreneurial devs to join us in building the world's first "Async AI Software Engineer" DMs open :)

More than a clinical milestone – this marks real momentum for our lead asset. Our first-in-class oral therapeutic, ENV-294, cleared a major Phase I milestone with favorable safety results and it's showing potential to transform care for #atopicdermatitis patients. Read more: businesswire.com/news/home/2… Why does this matter? Because 200M people worldwide live with atopic dermatitis—yet, there’s a massive unmet need for safe, effective, and convenient options. We are excited to be launching our Phase 1b trial later this year, designed to further evaluate safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy in atopic dermatitis patients… stay tuned. #DrugDiscovery #AI #ClinicalTrials #Biotech #Inflammation

Climate resilience is a new market being built in real time. At our #SFClimateWeek2025 panel on Engineering Global Resilience, leaders from Google, Gridware, Understory & Nephila shared challenges & new tech approaches to managing climate risk 👇 wireframevc.com/community/sf…

🚀 We’ve been backed by leading investors behind @SpaceX, @amazon, and other world-changing companies, and now we’re adding one of the biggest names in #pharma to our list. Today, we’re excited to share that Sanofi has joined our Series C syndicate, bringing the total raise to $150M! Our platform leverages #AI to sequence #lifeschemistry and beats  industry averages for #drugdiscovery across time, cost, and outcomes. We’re just getting started. We have several more clinical trials set to start this year… stay tuned! 🔗 Read more: businesswire.com/news/home/2… #biotech #innovation #learningfromlife

The US battery storage market will 10x by 2035. Without optimization, billions get left on the table. Portco @tybaenergy is the autopilot for batteries, ensuring assets sell power at peak value—turning volatility to profit. Read about their $13.9M Series A heatmap.news/climate-tech/ty…

#Asthma affects >250M people worldwide and has seen no new meaningful drug approvals in over a decade. Today, Enveda is announcing  that we are expanding our first-in-class lead asset, ENV-294 in asthma, along with a world-class Asthma Advisory Board. Read more here: tinyurl.com/eczpyanc #biotech #AI #innovation

The energy industry is facing unprecedented changes — rising #electricity demand, evolving markets, and a shifting political landscape. The road ahead is full of opportunities for #energystorage, but also new challenges. We share four predictions for 2025 bit.ly/42JPunB

We’re thrilled to introduce something special today… The inaugural issue of 𝗜𝗻-𝗩𝗲𝗱𝗮, a periodic collection of our thoughts and findings at the intersection of technology, science, and humanity. We believe sharing the stories, breakthroughs, and perspectives that shape our world, industry, and lives is essential. In each issue, we’ll give you a window into the advancements, bold ideas, and relentless dedication that drive us forward. In-Veda is more than just an online publication, it’s a reflection of who we are as a company, a community, and as people. Whether you’re an industry leader, partner, investor, or a passionate advocate for science and patient care, we invite you to engage with our vision and be part of this journey. Welcome to In-Veda. Read more: enveda.com/in-veda